Triple-Drug cocktail aims to extend life in tough stomach cancer
NCT ID NCT07309185
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding two drugs (adebrelimab and famitinib) to standard chemotherapy (irinotecan) can help people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. About 66 participants will be randomly assigned to receive either the three-drug combo or irinotecan alone. The main goal is to see if the combo delays cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab, famitinib malate, and irinotecan
What this could lead to
If successful, this combination could offer a new treatment option for advanced gastric cancer patients who have run out of standard options.
What could go wrong
This is a small, early-phase exploratory study with only 66 participants, so results may not apply broadly. The combination also carries risks of side effects from multiple drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-••••